文献速递骨肿瘤创伤骨科

BMP-2是否与小鼠骨肉瘤模型中的肿瘤生长和成骨细胞分化相关?

Is Use of BMP-2 Associated with Tumor Growth and Osteoblastic Differentiation in Murine Models of Osteosarcoma?
PubMed 文献 · Clin Orthop Relat Res · 2020-01-01

该研究通过基因修饰和 exogenous rhBMP-2 应用,在多种小鼠骨肉瘤模型中评估 BMP-2 信号对肿瘤细胞增殖、成骨分化和局部/全身肿瘤负荷的影响。结果显示 BMP-2 对局部肿瘤生长的影响不一致,且不持续诱导成骨分化,肺转移发生率无差异。结论支持在骨肉瘤保肢术后避免使用 BMP-2。

要点

  • BMP-2 对小鼠骨肉瘤局部生长影响不一,可促进部分细胞系肿瘤生长。
  • BMP-2 不持续诱导骨肉瘤细胞成骨分化,分化反应不可预测。
  • 外源性 rhBMP-2 同样增加 143b 局部肿瘤体积,支持避免保肢术后使用。

核心结论

  • 异位 BMP-2 信号对小鼠骨肉瘤局部肿瘤增殖影响不可预测,且不持续导致细胞系分化。
  • 结果支持避免在骨肉瘤患者保肢术后使用 BMP-2。

研究设计与样本

  • 研究使用 143b、SaOS-2 和 DLM8-M1 骨肉瘤细胞系,通过 PiggyBac 转座子系统转染 BMP-2 cDNA 或空载体。
  • 细胞注射到 NOD-SCID 小鼠(143b 和 SaOS-2 异种移植)或 C3H 小鼠(DLM8-M1 同系模型)胫骨近端。
  • 另将 rhBMP-2 浸泡或无菌水浸泡的可吸收胶原海绵植入 143b 注射部位旁,比较外源 BMP-2 效果。

主要发现

  • 组成型 BMP-2 表达增加 143b 细胞体外增殖(吸光度 1.2 ± 0.1 对比 0.89 ± 0.1,平均差 0.36 [95% CI 0.12 至 0.6];p = 0.01),对 SaOS-2 和 DLM8-M1 增殖无影响。
  • 组成型 BMP-2 表达使 143b 和 DLM8-M1 局部肿瘤体积增大(143b:307.2 ± 106.8 mm 对比 1316 ± 387.4 mm,平均差 1009 mm [95% CI 674.5 至 1343];p < 0.001;DLM8-M1 第四周:0 mm 对比 326.1 ± 72.8 mm,平均差 326.1 mm [95% CI 121.2 至 531];p = 0.009),但轻度减少 SaOS-2 局部肿瘤生长(9.5 x 10 ± 8.3x10 光子/s 对比 9.3 x 10 ± 1.5 x 10 光子/s,平均差 8.6 x 10 光子/s [95% CI 5.1 x 10 至 1.2 x 10];p < 0.001)。
  • 外源性 rhBMP-2 应用增加 143b 局部肿瘤体积(495 ± 91.9 mm 对比 1335 ± 102.7 mm,平均差 840.3 mm [95% CI 671.7 至 1009];p < 0.001)。
  • 所有实验条件下,实验组与对照组肺转移发生率无差异。

关键数值与推荐

  • 组成型 BMP-2 表达使 DLM8-M1 细胞下调早期标志物结缔组织生长因子(平均 ΔCt 0.2 ± 0.1 对比 0.6 ± 0.1;p = 0.002)并上调 Runx-2(平均 ΔCt -0.8 ± 0.1 对比 -1.1 ± 0.1;p = 0.002)。
  • 组成型 BMP-2 表达使 SaOS-2 细胞上调 Osterix(平均 ΔCt -2.1 ± 0.6 对比 -3.9 ± 0.6;p = 0.002)。
  • 143b 细胞成骨分化未见差异。

临床怎么用

  • 临床应避免在骨肉瘤患者保肢术后使用 BMP-2,因其可能促进对 BMP-2 介导成骨分化反应差的骨肉瘤细胞生长。
  • BMP-2 的成骨分化潜力在临床中不可预测,可能促进镜下残留肿瘤负荷生长。

局限性

  • 研究为小鼠模型,结果外推到人类需谨慎。
  • BMP-2 对局部肿瘤生长的影响在不同细胞系和模型中不一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The putative benefit of rhBMP-2 is in the setting of limb reconstruction using structural allografts, whether it be allograft-prosthetic composites, osteoarticular allografts, or intercalary segmental grafts. There are also potential advantages in augmenting osseointegration of uncemented endoprosthetics and in reducing infection. Recombinant human BMP-2 might mitigate nonunion in structural allograft augmented osteosarcoma limb salvage surgery; however, its use is limited because of concerns about the prooncogenic effects of the agent. QUESTIONS/PURPOSES: (1) To assess if BMP-2 signaling influences osteosarcoma cell line growth. (2) To characterize degree of osteosarcoma cell line osteoblastic differentiation in response to BMP-2. (3) To assess if BMP-2 signaling has a consistent effect on local or systemic tumor burden in various orthotopic murine models of osteosarcoma. METHODS: In this study, 143b, SaOS-2 and DLM8-M1 osteosarcoma cell lines were transfected with BMP-2 cDNA controlled by a constitutive promoter (experimental) or an empty vector (control) using a PiggyBac transposon system. Cellular proliferation was assessed using a quantitative MTT colorimetric assay. Osteoblastic differentiation was compared between control and experimental cell lines using quantitative real-time polymerase chain reaction of the osteoblastic markers connective tissue growth factor, Runx-2, Osterix, alkaline phosphatase and osteocalcin. Experimental and control cell lines were injected into the proximal tibia of either NOD-SCID (143b and SaOS-2 xenograft model), or C3H (DLM8-M1 syngeneic model) mice. Local tumor burden was quantitatively assessed using tumor volume caliper measurements and bioluminescence, and qualitatively assessed using post-mortem ex vivo microCT. Lung metastasis was qualitatively assessed by the presence of bioluminescence, and incidence was confirmed using histology. rhBMP-2 soaked absorbable collagen sponges (experimental) and sterile-H2O soaked absorbable collagen sponges (control) were implanted adjacent to 143b proximal tibial cell line injections to compare the effects of exogenous BMP-2 application with endogenous upregulation. RESULTS: Constitutive expression of BMP-2 increased the in vitro proliferation of 143b cells (absorbance values 1.2 ± 0.1 versus 0.89 ± 0.1, mean difference 0.36 [95% CI 0.12 to 0.6]; p = 0.01), but had no effect on SaOS-2 and DLM8-M1 cell proliferation. In response to constitutive BMP-2 expression, 143b cells had no differences in osteoblastic differentiation, while DLM8-M1 cells downregulated the early marker connective tissue growth factor (mean ΔCt 0.2 ± 0.1 versus 0.6 ± 0.1; p = 0.002) and upregulated the early-mid range marker Runx-2 (mean ΔCt -0.8 ± 0.1 versus -1.1 ± 0.1; p = 0.002), and SaOS-2 cells upregulated the mid-range marker Osterix (mean ΔCt -2.1 ± 0.6 versus -3.9 ± 0.6; p = 0.002). Constitutive expression of BMP-2 resulted in greater 143b and DLM8-M1 local tumor volume (143b: 307.2 ± 106.8 mm versus 1316 ± 387.4 mm, mean difference 1009 mm [95% CI 674.5 to 1343]; p < 0.001, DLM8-M1 week four: 0 mm versus 326.1 ± 72.8 mm, mean difference 326.1 mm [95% CI 121.2 to 531]; p = 0.009), but modestly reduced local tumor growth in SaOS-2 (9.5 x 10 ± 8.3x10 photons/s versus 9.3 x 10 ± 1.5 x 10 photons/s, mean difference 8.6 x 10 photons/s [95% CI 5.1 x 10 to 1.2 x 10]; p < 0.001). Application of exogenous rhBMP-2 also increased 143b local tumor volume (495 ± 91.9 mm versus 1335 ± 102.7 mm, mean difference 840.3 mm [95% CI 671.7 to 1009]; p < 0.001). Incidence of lung metastases was not different between experimental or control groups for all experimental conditions. CONCLUSIONS: As demonstrated by others, ectopic BMP-2 signaling has unpredictable effects on local tumor proliferation in murine models of osteosarcoma and does not consistently result in osteosarcoma cell line differentiation. Further investigations into other methods of safe bone and soft tissue healing augmentation and the use of differentiation therapies is warranted. CLINICAL RELEVANCE: Our results indicate that BMP-2 has the potential to stimulate the growth of osteosarcoma cells that are poorly responsive to BMP-2 mediated osteoblastic differentiation. As this differentiation potential is unpredictable in the clinical setting, BMP-2 may promote the growth of microscopic residual tumor burden after resection. Our study provides further support for the recommendation to avoid the use of BMP-2 after limb-salvage surgery in patients with osteosarcoma.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Kendal JK, Singla A, Affan A, et al. Is Use of BMP-2 Associated with Tumor Growth and Osteoblastic Differentiation in Murine Models of Osteosarcoma? Clin Orthop Relat Res. 2020. PMID: 33275394. doi:10.1097/CORR.0000000000001422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。